{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".58","upperLimit":".99","value":".71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Median Progression Free Survival of participants reported after 2 years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Erlotinib\n\nerlotinib hydrochloride\n\npemetrexed disodium\n\nquality-of-life assessment\n\nintensity-modulated radiation therapy","id":"OG000","title":"Erlotinib"}],"paramType":"MEDIAN","populationDescription":"Data corresponds to Phase II patients.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Median Progression Free Survival","type":"SECONDARY","unitOfMeasure":"years"}